Size can be a restricting factor when introducing single-use technologies into a pre-existing facility according to BMS, which hopes to integrate disposable equipment at a US-based site.
Modular facilities and single-use systems are fast becoming a standard part of the bioproduction infrastructure as industry looks to mitigate future capacity constraints.
Biomanufacturers have fully embraced disposable technologies but the market is controlled by a handful of vendors keeping equipment costs high, our reader survey reveals.
Industry’s uptake of stainless steel systems continues to fall as biomanufacturers move away from large volume blockbuster biologics, according to GE Healthcare.
Single-use is the future but stainless steel bioreactors will always play a role in drug production says an expert, who thinks firms could do worse than consult a CMO before deciding in which technology to invest.
Phage manufacturers are yet to take advantage of single-use techs says Cellexus, which hopes bioreactors employing its ‘air lift’ system will win it customers in this emerging niche.
Increased efficiency, local manufacturing and specialty products are driving demand for smaller more flexible facilities, according to bioprocessing consultant Howard Levine.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
Retrofitting stainless steel plants with single-use systems is driving a “paradigm shift” in drug production but creates logistical problems, an AAPS panel said.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
